3
H index
1
i10 index
298
Citations
Don Husereau : Citation Profile
| RESEARCH PRODUCTION: 19 Articles RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
9 years (2013 - 2022). Relations with other researchers
Works with: Authors registered in RePEc who have co-authored more than one work in the last five years with Don Husereau. | Is cited by:
| Cites to:
|
Main data
Where Don Husereau has published?
| Journals with more than one article published | # docs |
|---|---|
| Applied Health Economics and Health Policy | 6 |
| PharmacoEconomics | 5 |
| PLOS ONE | 3 |
| The European Journal of Health Economics | 3 |
Recent works citing Don Husereau (2024 and 2023)
| Year | Title of citing document |
|---|---|
| 2023 | Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms: cross-country evidence from weighted-average least squares estimation. (2022). Czypionka, Thomas ; Rohrling, Gerald ; Reiss, Miriam ; Pock, Markus ; Berger, Michael. In: LSE Research Online Documents on Economics. RePEc:ehl:lserod:116928. Full description at Econpapers || Download paper |
| 2023 | . Full description at Econpapers || Download paper |
| 2023 | . Full description at Econpapers || Download paper |
| 2023 | . Full description at Econpapers || Download paper |
| 2023 | . Full description at Econpapers || Download paper |
| 2023 | The Cost-Effectiveness of Adjunctive Lifestyle Interventions for the Management of Cancer: A Systematic Review. (2023). Haines, Terry ; Truby, Helen ; Mortimer, Duncan ; Shersher, Violetta ; Gallagher, Andrew. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:21:y:2023:i:2:d:10.1007_s40258-022-00759-4. Full description at Econpapers || Download paper |
| 2023 | Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands. (2023). Postma, A J ; Quist, S W ; Jong, L A ; Myren, K J. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:24:y:2023:i:9:d:10.1007_s10198-022-01556-5. Full description at Econpapers || Download paper |
| 2023 | Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran. (2023). Jafari, Abdosaleh ; Hajahmadi, Marjan ; Jalali, Farideh Sadat ; Ravangard, Ramin. In: Health Economics Review. RePEc:spr:hecrev:v:13:y:2023:i:1:d:10.1186_s13561-023-00457-4. Full description at Econpapers || Download paper |
| 2023 | Costs and Cost-Effectiveness of Biomedical, Non-Surgical HIV Prevention Interventions: A Systematic Literature Review. (2023). Gafos, Mitzy ; Quaife, Matthew ; Terris-Prestholt, Fern ; Bozzani, Fiammetta M ; Torres-Rueda, Sergio ; Malhotra, Shelly ; Medley, Graham F ; Giddings, Rebecca ; Indravudh, Pitchaya P. In: PharmacoEconomics. RePEc:spr:pharme:v:41:y:2023:i:5:d:10.1007_s40273-022-01223-w. Full description at Econpapers || Download paper |
Works by Don Husereau:
| Year | Title | Type | Cited |
|---|---|---|---|
| 2013 | Capturing Value from Health Technologies in Lean Times In: C.D. Howe Institute Commentary. [Full Text][Citation analysis] | article | 2 |
| 2014 | A Systematic Review of Cost-Sharing Strategies Used within Publicly-Funded Drug Plans in Member Countries of the Organisation for Economic Co-Operation and Development In: PLOS ONE. [Full Text][Citation analysis] | article | 9 |
| 2018 | Economic evaluations of eHealth technologies: A systematic review In: PLOS ONE. [Full Text][Citation analysis] | article | 3 |
| 2020 | Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis In: PLOS ONE. [Full Text][Citation analysis] | article | 0 |
| 2019 | Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB) In: Medical Decision Making. [Full Text][Citation analysis] | article | 0 |
| 2015 | How do Economic Evaluations Inform Health Policy Decisions for Treatment and Prevention in Canada and the United States? In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 1 |
| 2016 | Using Phase-Based Costing of Real-World Data to Inform Decision–Analytic Models for Atrial Fibrillation In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 0 |
| 2018 | Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 0 |
| 2020 | Systematic Review of Economic Evaluations of Services Provided by Community Pharmacists In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 0 |
| 2022 | Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 5 |
| 2022 | Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.(2022) In: The European Journal of Health Economics. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 5 | article | |
| 2022 | Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.(2022) In: PharmacoEconomics. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 5 | article | |
| 2022 | Correction to: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 0 |
| 2013 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 278 |
| 2013 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement.(2013) In: PharmacoEconomics. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 278 | article | |
| 2021 | Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 0 |
| 2015 | Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration In: PharmacoEconomics. [Full Text][Citation analysis] | article | 0 |
| 2018 | Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment In: PharmacoEconomics. [Full Text][Citation analysis] | article | 0 |
| 2021 | Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT) In: PharmacoEconomics. [Full Text][Citation analysis] | article | 0 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated December, 10 2023. Contact: CitEc Team